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Background: This study aimed to compare serum cortisol concentrations in cognitively healthy elderly and in
subjects with cognitive impairment no dementia (CIND) and dementia, besides to evaluate these concentra-
tions according to apolipoprotein E genotype (APOE).
Methods: Three-hundred and nine elderly enrolled in the Pietà Study (Brazil) were divided in 3 groups:
control (n = 158), CIND (n = 92) and dementia (n = 59) and had concentrations of morning serum cortisol
measured. Hormone concentrations were measured by chemiluminescence and APOE genotypes were deter-
mined by PCR followed by restriction fragment length polymorphism (RFLP).
Results:Medians of cortisol concentrations (μg/dl) for the groups were 12.14 (interquartile range— IQR 6.34)
for control, 13.65 (IQR 5.88) for CIND and 14.47 (IQR 7.35) for dementia. Signiﬁcant differences were ob-
served for control vs. CIND (P = 0.003), control vs. dementia (P = 0.001), but not for CIND vs. dementia
(P = 0.269). No association was observed between cortisol concentrations and APOE genotype among the
groups (P = 0.348).
Conclusions: The elevation in cortisol concentrations is associated with dementia, independently of APOE ge-
notypes. Further studies are required to understand if elevation of cortisol is an initial event and how hippo-
campal damage and the loss of hypothalamus–pituitary–adrenal (HPA) axis inhibition may affect its
concentrations.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Population aging is nowadays a world phenomenon [1]. One of its
consequences is the increase of chronic degenerative diseases, such as
dementia, [2] a syndrome characterized by progressive and global de-
cline of cognitive functions, including memory impairment and at least
aphasia, apraxia, agnosia or disturbance in executive functioning [3].
Among the possible causes of dementia, Alzheimer's disease (AD)
is the most common [4]. It is also the most frequent age-related neu-
rodegenerative pathology, [5] being responsible for at least half of the
cases of the syndrome, [6] followed by vascular dementia and mixed
dementia, characterized by simultaneous occurrence of both AD and
cerebrovascular disease [6,7].oprotein E gene; CIND, cogni-
ittee of the Federal University
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rights reserved.AD is considered a complex polygenic and multifactorial disorder
[8]. The apolipoprotein E gene (APOE) that codiﬁes a glycoprotein
which plays a role in metabolism and transport of lipids in the organ-
ism [9] has been related as the main genetic risk factor for the disease,
particularly for carriers of ε4 allele [8–11].
There are intermediate categories between cognitive normal state
and dementia in old people, classiﬁed as cognitive impairment no de-
mentia (CIND) [12] or mild cognitive impairment (MCI) [13]. CIND is
deﬁned as impairments in memory and/or other cognitive domains
not sufﬁciently severe to be classiﬁed as dementia and has been sug-
gested to evaluate cognitive impairment in large cohort studies [14].
CIND differs from the other deﬁnitions of pre-dementia because it is
less restrictive and includes subjects with cerebral vascular changes
and other known causes of cognitive impairment and not only those
with potential to develop AD, as MCI [15,16].
Therefore, since individuals with CIND are at increased risk of devel-
oping dementia it is important to investigate and better comprehend
characteristics and risk factors related to this condition to develop strat-
egies, to prevent or delay the onset of the syndrome [17,18].
Cortisol is a glucocorticoid hormone associated with organism re-
sponse to stress. It is produced by the cortex of adrenal glands, follows
a circadian rhythm and mediates many metabolic processes, such as
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vascular output, redistributing blood ﬂow and modulating the immune
system [19,20].
The hormone is regulated by the hypothalamus–pituitary–adrenal
(HPA) axis. Its acute release by an absolute or relative stressor in-
hibits further release by negative feedback [21]. Besides the pituitary
and the hypothalamus, the hippocampus has also been implicated in
the regulation of glucocorticoid activity [22].
The activation of the HPA axis can be considered a basic adaptive
mechanism in response to change. However, prolonged activation of
this system is a risk to the organism's health [21]. Chronic cortisol ris-
ing in response to a continued stress has been related to various
chronic diseases and metabolic changes, including diabetes, hyper-
tension, dyslipidemia and immunosuppression [19,23].
Cortisol can easily cross the blood–brain barrier, where it can in-
ﬂuence learning and memory by binding to brain receptors involved
with these cognitive domains in speciﬁc areas, such as the hippocam-
pus, the amygdala and frontal lobes [21,24]. Changes in its concentra-
tions can also cause impairments in attention and perception [25].
High concentrations of cortisol have been observed in individuals
with hippocampal atrophy, cognitive decline and it has been debated
if this increase is a cause or a consequence of these processes
[24,26–28].
2. Materials and methods
2.1. Study design
The Pietà study is an epidemiological investigation about healthy
brain aging in the elderly (age ≥ 75 y). This population-based study
was conducted in Caeté, Minas Gerais, Brazil. Methods and baseline
characteristics of the participants were previously reported in detail
elsewhere [2]. The study protocol was approved by the Ethics Com-
mittee of the Federal University of Minas Gerais (COEP/UFMG) and
all participants or their legal representatives signed the written
informed consent.
2.2. Participants
As shown in Table 1, 309 patients were included in this study: 158
controls, 92 individuals with CIND and 59 with dementia. Age and sex
were informed during interview and BMI was calculated after assess-
ment of height and weight during clinical evaluation. Participants
went through comprehensive clinical and neurological examination,
including cognitive and functional assessments. The ones with
suspected cognitive impairment and a subset of cognitively healthy
individuals were referred to complementary neuropsychological and
functional evaluations [2]. CIND [17] and dementia [29] were deﬁned
according to standard diagnostic criteria.Table 1
Characteristics of the study population classiﬁed according the groups.
Category Control
n = 158 (%)
CIND
n = 92 (%)
Dementi
n = 59 (
Gender Male 64 (53.3) 33 (27.5) 23 (19.2)
Female 94 (49.7) 59 (31.2) 36 (19.0)
Age ≤79 y 96 (58.9)⁎⁎ 43 (26.4) 24 (14.7)
>79 y 62 (42.5)⁎ 49 (33.6) 35 (24.0)
BMI b25.0 kg/m2 54 (44.6) 46 (38.0) 21 (17.4)
≥25.0 kg/m2 83 (58.9) 36 (25.5) 22 (15.6)
Chi-square test.
Signiﬁcant by residuals test: ⁎less frequent; ⁎⁎more frequent.
CIND — cognitive impairment no dementia.
P1-value — comparison among control, CIND and dementia.
P2-value — comparison among control and CIND and dementia combined.2.3. Cortisol measurements
Blood samples were collected in the morning after an overnight
fast. Serum cortisol concentrations were determined by chemilumi-
nescence using DPC Bayer® kit, according to the manufacturer's pro-
tocol and analyzed in Advia Centaur® equipment. The interassay CVs
for 5 different serum concentrations (from 3.88 to 37.15 μg/dl) were
4.98–6.58%. The analytical assay sensitivity was 0.20 μg/dl; functional
assay sensitivity at b20% interassay CV, 0.80 μg/dl.
2.4. APOE genotyping
Genomic DNA for APOE genotyping was extracted from total blood
samples in EDTA. DNA samples were then ampliﬁed by polymerase
chain reaction (PCR), followed by digestion with HhaI and restriction
fragment length polymorphism (RFLP) analysis to determine alleles
ε2, ε3 and ε4, as previously described by Hixson et al. [30].
2.5. Statistical analysis
Analyses were performed with SPSS ver 13.0 (Chicago, IL). Normal
distribution of data was checked by the Shapiro–Wilk test. Serum corti-
sol concentrations, age and BMIwere analyzed by the Kruskal–Wallis or
Mann–Whitney test followed by the Bonferroni correction. Sex, age and
BMI were also analyzed by the asymptotic Pearson χ2 with residuals
test. Level of statistical signiﬁcance was considered a P b 0.05.
3. Results
3.1. Baseline analyses
From the 309 individuals that participated of this study, 120 (38.8%)
were male and 189 (61.2%) were female. There was no difference
among the groups according to gender (Table 1). Median age (y) was
signiﬁcantly different among groups (P = 0.009): 78.0 (interquartile
range — IQR 5.0) for control, 80.0 (IQR 6.0) for CIND and 82.0 (IQR
7.0) for dementia. Differences were observed for control vs. CIND
(P = 0.009) and control vs. dementia (P b 0.001), but not for CIND vs.
dementia (P = 0.062). The variable age was divided in 2 categories,
according to the median of the participants (less or more than 79 y)
and also showed signiﬁcant differences for group (P = 0.012). Individ-
uals aged ≤ 79 y were more frequent in the control group and less fre-
quent in the dementia group. The opposite was observed for subjects
aged > 79 y (Table 1).
Median BMI for the groups was 26.02 (IQR 5.77) for control; 24.36
(IQR 6.52) for CIND and 25.15 (IQR 9.00) for dementia. BMI was also
categorized as follows: b25.0 kg/m2 (underweight or normal weight)
and ≥25.0 kg/m2 (overweight or obese) (Table 1). Neither of the 2
analyses with BMI according to groups showed signiﬁcant differences
(P = 0.056 and P = 0.053, respectively).a
%)
CIND + dementia




56 (46.7) 120 (38.8) NS NS
95 (50.3) 189 (61.2)
⁎ 67 (41.1) 163 (52.8) 0.012 0.004
⁎⁎ 84 (57.5) 146 (47.2)
67 (55.4) 121 (46.2) 0.053 0.021
58 (41.1) 141 (53.8)
Fig. 1. Serum cortisol levels (μg/dl) according to groups (control, CIND and dementia).
Table 2
Median of serum cortisol levels according to APOE genotypes.
Genotype (n) Cortisol levels (μg/dl) P-value
ε2ε4 (12) 10.99 IQR 4.62 NS
ε2ε2, ε2ε3 (51) 13.70 IQR 5.12
ε3ε3 (162) 13.41 IQR 5.69
ε3ε4, ε4ε4 (84) 12.35 IQR 6.62
IQR — interquartile range.
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versus CIND and dementia combined. Again, there weren't differ-
ences relative to gender between the groups (P = NS) (Table 1). Me-
dian age (y) for CIND and dementia combined was 81.0 (IQR 7.0).
When the ages were compared there was a signiﬁcant difference
(P b 0.001) between the groups. The same was observed when age
was categorized as described before (P = 0.004) (Table 1).
Median BMI (kg/m2) for CIND and dementia combined was 24.78
(IQR 7.72). Once again, when compared to control, there was no dif-
ference (P = NS). However, when BMI was categorized, there was a
signiﬁcant difference between these two groups (P = 0.021). Indi-
viduals with BMI b 25 kg/m2 were more frequent in CIND and de-
mentia combined and the opposite was observed for subjects with
BMI ≥ 25.0 kg/m2.3.2. Cortisol concentrations
The medians of serum cortisol concentrations in μg/dl (nmol/l) for
the groups were 12.14 IQR 6.34 (334.94 IQR 174.92) for control; 13.65
IQR 5.88 (376.60 IQR 162.23) for CIND and 14.47 IQR 7.35 (399.22
IQR 202.79) for dementia. There was a signiﬁcant difference among
them (P = 0.003). Differences were observed for control vs. CIND
(P = 0.003), control vs. dementia (P = 0.001), but not for CIND vs.
dementia (P = 0.269) (Fig. 1). Median serum cortisol concentration
in μg/dl (nmol/l) for CIND and dementia combined was 13.89 IQR
6.43 (383.23 IQR 177.40). A difference was also observed for control
vs. the latter group (P b 0.001) (Fig. 2). The serum cortisol concentra-
tions were compared according the APOE genotypes inter and
intragroups. There was no association between median of cortisol
concentrations and APOE genotypes (P = 0.348) (Table 2).Fig. 2. Serum cortisol levels (μg/dl) by grouping individuals in CIND and dementia
compared to control.4. Discussion
The present study evaluated the association of cortisol, APOE ge-
notypes and CIND/dementia in a speciﬁc elderly cohort from Brazil.
This special group, with a common genetic background and living in
a small city, permits to evaluate biological changes in a population
that had similar habits along life. Gender distribution did not change
between groups, although some studies have demonstrated a higher
female frequency in groups with dementia, when compared to male
[31–33].
We observed older individuals in CIND and dementia groups
when compared to control, even if classifying participants with
≤79 y. This ﬁnding was expected, since there is a strong correlation
between age and dementia [31,34]. Nitrini et al. [35] reviewed the
prevalence of dementia in Latin-America studies and found the fol-
lowing rates according to age group: 2.4% (65–69 y), 7.0% (75–79 y)
and 20.2% (85–89 y).
Our results also showed that older individuals have a higher prob-
ability to develop CIND. Although few works have investigated the
correlation between age and this condition, the Canadian Study of
Health and Aging also observed that the prevalence of CIND increased
with age [17].
Obesity can be a risk factor for dementia, mainly associated to low
and chronic inﬂammation state in adipose tissue. However, this was
not a retrospective study, thus limiting this analysis. Individuals
with BMI b 25.0 kg/m2 were more frequent in CIND and dementia
combined when compared to control probably because feeding in pa-
tients with dementia is impaired due to their inherent limitations.
Moreover, according to Atti et al. [36], a lower BMI and loss of weight
also could be secondary factors to the pathophysiological alterations
in preclinical dementia.
The present study showed that concentrations of morning serum
cortisol were higher in patients with dementia, intermediate in sub-
jects with CIND and lower in controls. In the ﬁrst analysis, the differ-
ence was seen between control and dementia and also between
control and CIND. In agreement with our results, Gil-Bea et al. [24]
and Csernansky et al. [27] also found higher concentrations of cortisol
in patients with AD, either in cerebrospinal ﬂuid or in plasma.
One hypothesis to explain these results is that higher concentra-
tions of cortisol have led to impairments in global cognition, since
chronic exposure to high glucocorticoids concentrations during
aging has been associated with smaller hippocampal volume, death
of hippocampal neurons and cognitive decline [24–26]. Then, in-
creases in cortisol secretion in later life could start MCI and/or the
hippocampal atrophy related to this condition.
Beluche et al. [37] examined the relationship between salivary corti-
sol measured three time points on the day and cognitive domains eval-
uated at baseline, 2- and 4-year follow-up in elderly. The results showed
that high morning cortisol concentration was associated with low cog-
nitive performance mainly in cross-sectional analysis and that slower
cortisol elimination rates were more predictive of cognitive decline in
speciﬁc domains (principally non-verbal functioning in men and verbal
ﬂuency in women) in longitudinal analyses. The authors suggested that
alterations in HPA axis response could be associated with speciﬁc
changes in memory and executive function but not with signiﬁcant
alteration in global cognitive function.
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tion between morning concentrations of cortisol and cognitive func-
tion assessed at baseline or annual cognitive decline. In addition, the
authors did not ﬁnd a relationship between the hormone and the
risk of dementia or AD [28].
Lind et al. [38] reported signiﬁcantly higher concentrations of sal-
ivary cortisol, 15 min after awakening in patients with MCI, com-
pared to controls. Canadian researchers found similar results, since
concentrations of salivary cortisol were signiﬁcantly lower in controls
compared to MCI and to AD, with intermediate concentrations in pa-
tients with MCI [39]. Even though there isn't a report on the literature
about concentrations of cortisol and CIND, our results are in agree-
ment with these studies, which found higher concentrations of the
hormone in a pre-dementia state.
In contrast, Gil-Bea et al. [24] and Csernansky et al. [27] did not
ﬁnd higher concentrations of cortisol in individuals with MCI (even
when this group was divided in MCI stable or in MCI in progression
to AD), light AD or in controls, suggesting that the rising in cortisol
concentrations is not an initial event in AD. According to them, higher
concentrations of the hormone would be related to the progression of
the disease and does not have a prognostic value in AD. However, it is
possible that rising of this hormone could be related to the loss of the
HPA axis inhibition because of hippocampal damage due to AD prog-
ress [22,27]. The hypothesis that hippocampal damage would result
in high concentrations of the hormone also explains our results,
since increased cortisol concentrations were observed between con-
trol and CIND groups, but not between CIND and dementia.
Although polymorphisms in APOE gene are classically associated
to dementia development, an association between cortisol concentra-
tions and APOE genotypes was not observed in the present study.
These results suggest that cortisol is an independent risk factor from
the genetic characteristics to CIND and dementia. Differently from
our results, Gil-Bea et al. [24] reported that patients with AD and at
least one APOE ε4 allele had higher concentrations of cortisol when
compared to patients that were not carriers of this allele or to those
that were ε4 carriers in the control group, MCI stable or MCI in pro-
gression to AD. Peskind et al. [40] and Agosta et al. [41] also found
that patients with probable AD and carriers of ε4 showed higher
rates of hippocampal atrophy compared to non-carriers. These dis-
crepant results suggest that the relationship between cortisol and
APOE genotype could be dependent on other genetic factors that
vary according the population.
In summary, our results showed that concentrations of morning
serum cortisol are higher in individuals with dementia, intermediate
in individuals with CIND and lower in controls, independently of
APOE genotype. It is suggested that this elevation can be a conse-
quence of hippocampal damage, related to the loss of HPA axis inhibi-
tion, or that previous elevation of the hormone concentrations during
life could contribute to hippocampal damage and possibly triggers
CIND and dementia. However, a prospective research is needed to
further clarify the mechanisms underlying this question, including
the association with APOE isoforms.Acknowledgments
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